MPTP-induced parkinsonism as a model for Parkinson's disease
- PMID: 2694734
- DOI: 10.1111/j.1600-0404.1989.tb01780.x
MPTP-induced parkinsonism as a model for Parkinson's disease
Abstract
It is now well recognized that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce a syndrome in human and non-human primates similar to Parkinson's disease. This highly selective neurotoxin, which affects specific catecholaminergic nuclei in the brainstem, has provided an important new tool for the study of Parkinson's disease. In this article we review several specific areas related to current research on MPTP, including the question of disease progression, issues regarding the validity of the animal model induced by MPTP, the role of aging in regard to its neurotoxicity and Parkinson's disease, and new therapeutic strategies that have evolved from basic research with the compound. We conclude that both clinical and basic research stemming from the discovery of MPTP have provided valuable insights regarding both the cause and treatment of Parkinson's disease.
Similar articles
-
Animal models of parkinsonism.Pharmacol Toxicol. 1990 Aug;67(2):95-100. doi: 10.1111/j.1600-0773.1990.tb00792.x. Pharmacol Toxicol. 1990. PMID: 2123984 Review.
-
[MPTP: a new chapter in the history of Parkinson's disease].Riv Neurol. 1989 May-Jun;59(3):103-7. Riv Neurol. 1989. PMID: 2688042 Review. Italian.
-
MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease.Can J Neurol Sci. 1991 Feb;18(1):77-82. doi: 10.1017/s0317167100031346. Can J Neurol Sci. 1991. PMID: 2036621 Review.
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.Brain Res. 1996 Nov 25;741(1-2):185-96. doi: 10.1016/s0006-8993(96)00917-1. Brain Res. 1996. PMID: 9001722
-
[Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].Fortschr Neurol Psychiatr. 1989 Apr;57(4):142-8. doi: 10.1055/s-2007-1000755. Fortschr Neurol Psychiatr. 1989. PMID: 2656447 Review. German.
Cited by
-
Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases.Biomed J. 2022 Oct;45(5):733-748. doi: 10.1016/j.bj.2022.05.002. Epub 2022 May 11. Biomed J. 2022. PMID: 35568318 Free PMC article. Review.
-
The Role of Bioenergetics in Neurodegeneration.Int J Mol Sci. 2022 Aug 16;23(16):9212. doi: 10.3390/ijms23169212. Int J Mol Sci. 2022. PMID: 36012480 Free PMC article. Review.
-
Vitamin E Analog Trolox Attenuates MPTP-Induced Parkinson's Disease in Mice, Mitigating Oxidative Stress, Neuroinflammation, and Motor Impairment.Int J Mol Sci. 2023 Jun 9;24(12):9942. doi: 10.3390/ijms24129942. Int J Mol Sci. 2023. PMID: 37373089 Free PMC article.
-
The Importance of Drosophila melanogaster Research to UnCover Cellular Pathways Underlying Parkinson's Disease.Cells. 2021 Mar 6;10(3):579. doi: 10.3390/cells10030579. Cells. 2021. PMID: 33800736 Free PMC article. Review.
-
Resolvin D1 Attenuates Mpp+-Induced Parkinson Disease via Inhibiting Inflammation in PC12 Cells.Med Sci Monit. 2017 Jun 2;23:2684-2691. doi: 10.12659/msm.901995. Med Sci Monit. 2017. PMID: 28572562 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
